Bristol-Myers Squibb

Halal Rating :
Comfortable
Last Price $59.8
Market Cap $119.91b
1D Change

1.56 %

1 Year Change

12.22 %

Next Earnings Date

Yet to be announced

Company Overview

Bristol-Myers Squibb Company (BMY) is a biopharmaceutical company that discovers, develops, and delivers innovative medicines to help patients prevail over serious diseases. The company focuses on oncology, hematology, immunology, and cardiovascular disease. Their portfolio includes several leading pharmaceutical products such as Eliquis, Opdivo, and Revlimid.

Revenue Sources

Pass

After reviewing Bristol-Myers Squibb's product portfolio and revenue sources, their income primarily comes from the development and sale of pharmaceutical products. These products and services are considered halal as they provide medical treatments that improve human health and well-being. There is no evidence of significant revenue from prohibited sources such as alcohol, gambling, or other haram activities.

Reliance on Interest

Pass
Reporting Date Total Revenue Total Expense Interest Income Interest Expense Interest Income Ratio Interest Expense Ratio
Sept. 30, 2024 $11.89b $9.98b - - 0.00% 0.00%
June 30, 2024 $12.2b $10.64b - - 0.00% 0.00%
March 31, 2024 $11.87b $23.3b - - 0.00% 0.00%
Dec. 31, 2023 $11.48b $10.17b - - 0.00% 0.00%

Based on the financial data from the last four quarters, Bristol-Myers Squibb reported zero interest income and zero interest expense across all periods. This indicates that interest-based income and expenses are not material to the company's operations. The company's primary revenue comes from its core pharmaceutical business.

Operational Ethics

Pass

Bristol-Myers Squibb operates globally but maintains stringent ethical standards in its operations. While the company does business in various markets, there is no evidence of material ongoing collaboration with entities involved in human rights violations. The company has established compliance programs and ethical guidelines that govern its international operations.

Rating Justification

Member Vote

Agree: 1 Disagree: 1

Login to vote on this

Comments

1 Comments

Login to join the discussion

[email protected] | 7 months ago

It’s cheap and dependable dividend stocks-growth stock to buy.

| 0 Reply
0 0

Login to join the discussion


Recent News & Updates